aclidinium
aclidinium
(a-kli-din-ee-um) aclidiniumbromide,Tudorza
(trade name)Classification
Therapeutic: copd agentsPharmacologic: anticholinergics
Indications
Action
Therapeutic effects
Pharmacokinetics
Time/action profile (improvement in FEV1)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
Inhaln | within 1 hr | 2–4 hr | 12 hr |
Contraindications/Precautions
Adverse Reactions/Side Effects
Central nervous system
- headache
Ear, Eye, Nose, Throat
- worsening of narrow-angle glaucoma
Respiratory
- paradoxical bronchospasm
Genitourinary
- urinary retention
Miscellaneous
- immediate hypersensitivity reactions
Interactions
Drug-Drug interaction
↑ risk of adverse anticholinergic effects with other anticholingerics.Route/Dosage
Availability
Nursing implications
Nursing assessment
- Inhalation: Assess respiratory status (rate, breath sounds, degree of dyspnea, pulse) before administration and at peak of medication. Consult health care professional about alternative medication if severe bronchospasm is present; onset of action is too slow for patients in acute distress. If paradoxical bronchospasm (wheezing) occurs, withhold medication and notify health care professional immediately.
Potential Nursing Diagnoses
Ineffective airway clearance (Indications)Activity intolerance (Indications)
Implementation
- Inhalation: Administer every 12 hr. See for administration of inhalation medications.
- When aclidinium is administered concurrently with other inhalation medications, administer adrenergic bronchodilators first, followed by aclidinium, then corticosteroids. Wait 5 min between medications.
Patient/Family Teaching
- Instruct patient in proper use of inhaler and to take medication as directed. Omit missed doses and take next dose at the usual time; do not double doses. Advise patient to read Medication Guide before beginning therapy and with each Rx refill in case of changes.
- Advise patient to have a rapid-acting bronchodilator available for use at all times to treat sudden symptoms. Notify health care professional immediately if sudden shortness of breath occurs immediately after using aclidinium inhaler, if breathing becomes worse, if rescue inhaler is needed more often than usual, or if rescue inhaler does not work as well at relieving symptoms.
- Caution patient to avoid getting powder into eyes.
- Advise patient to inform health care professional if symptoms of new or worsened increased eye pressure (eye pain or discomfort, nausea or vomiting, blurred visions, seeing halos or bright colors around lights, red eyes), new or worsened urinary retention (difficulty urinating, painful urination, urinating frequently, urination in a weak stream or drips), or allergic reactions (rash, hives, swelling of the face, mouth, and tongue, breathing problems) occur.
- Advise patient to consult health care professional before taking any Rx, OTC, or herbal products or alcohol concurrently with this therapy. Caution patient also to avoid smoking and other respiratory irritants.
- Advise patient to notify health care professional if pregnancy is planned or suspected, or if nursing.
- Explain need for pulmonary function tests prior to and periodically during therapy to determine effectiveness of medication.
Evaluation/Desired Outcomes
- Decreased dyspnea.
- Improved breath sounds.